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Abstract:  
Objective: To assess the use of two-drug antiretroviral regimens (2DR) and virologic and 
immunologic outcomes compared to three-drug regimens (3DR) in the EuroSIDA cohort. 
Design:  Multicentre, prospective cohort study. 
Methods: Logistic regression was used to analyse the uptake and outcomes among HIV-
positive individuals who started  or switched to a 2DR compared to those on a 3DR. 
Virologic outcomes were assessed on-treatment as the proportion of individuals with 
controlled viral load (VL, <400 copies/mL), or with a composite modified FDA snapshot 
endpoint (mFDA), with mFDA success defined as controlled VL at 6- or 12-months for 
individuals with a known VL, no regimen changes, AIDS or death. Immunologic response 
was defined as a 100 cells/µL or a 25% increase in CD4 counts from baseline. 
Results:  Between 1/7/2010-31/12/2016, 423 individuals started or switched to a 2DR (8 
antiretroviral-naïve) and 4347 started a 3DR (566 naïve). Individuals on 2DR tended to have 
suppressed VL, higher CD4 cell counts and more comorbidities at baseline compared to those 
on 3DR.  There were no differences in the proportions of individuals who obtained on-
treatment or mFDA success, and no significant differences in the adjusted odds ratios for 
mFDA success or immunologic responses between the 2DR and 3DR groups at 6- or 12-
months. 
Conclusion: In routine clinical practice, 2DR were largely used for virologically suppressed 
individuals with higher cumulative exposure to ARVs and comorbidities. Virologic and 
immunologic outcomes were similar among those on 2DR or 3DR, although confounding by 
indication cannot be fully excluded due to the observational nature of the study. 
Key-words: HIV, Two-drug regimens, simplification, cART, NRTI-sparing regimens, dual 
therapy 
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Introduction: 
Combination antiretroviral treatment (cART), given as a three-drug regimen (3DR) 
consisting of two nucleot(s)ide reverse transcriptase inhibitors (NRTIs) together with a non-
nucleotide reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI) or integrase 
inhibitor (INSTI) has been the standard treatment for HIV for more than two decades.[1, 2] 
Although 3DRs are effective in maintaining virological suppression, lifelong treatment is 
needed, with increased concerns for long term toxicities and  drug-drug interaction,[3-5] 
especially as the population of people living with HIV (PLWHIV) ages.[6] One approach to 
address these concerns is treatment-simplification to NRTI-sparing two-drug regimens 
(2DR), consisting of exactly two active drugs, which has become feasible with the 
introduction of potent PIs and INSTIs. 
Randomized clinical trials (RCTs) are necessary to evaluate drug efficacy, and studies on 
2DR approaches have yielded promising results.  For example, studies of 2DR therapy with 
boosted PIs in combination with NRTIs have overall shown good ability to suppress viral 
replication,[7-9] and with the advent of INSTIs with high genetic barriers, potent antiretroviral 
(ARV) activity and low numbers of reported adverse effects,[10-12] the interest in diverse 
combinations of INSTI- and PI-based 2DRs has increased.[13-19]  However, RCTs are 
intrinsically limited by modest sample sizes and inclusion of highly selected groups of 
individuals. Findings from RCTs are thus not necessarily generalizable to the majority of 
PLWHIV seen in routine clinical care, as persons with co-existing comorbidities, low CD4 
cell counts or high-level HIV viremia are often underrepresented. Results from RCTs 
therefore need to be complemented by investigations in larger and more heterogeneous 
observational studies. 
As 2DR are now also included as class-sparing strategies under certain circumstances in 
European and North American  guidelines,[1, 2] 2DR use in clinical practice will presumably 
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increase in the coming years.  However, there have been only a few studies assessing the 
performance of 2DR in real-life settings, based on relatively small cohorts and/or selected 
patient groups with limited heterogeneity.[20-23]  Here we analysed the uptake of 2DRs, factors 
associated with starting or switching to a 2DR in the European based EuroSIDA cohort, and 
virologic and immunologic outcomes of using 2DRs compared 3DRs in this large, 
heterogeneous, population of PLWHIV seen in routine clinical care. 
Methods: 
Study design – the EuroSIDA cohort: 
This investigation was conducted as part of the EuroSIDA study, a prospective observational 
cohort study that currently holds data on more than 23,000 PLWHIV in 35 European 
countries, Israel and Argentina. The main objective of the study is to describe the long-term 
clinical prognosis of PLWHIV in Europe (https://www.chip.dk/Studies/EuroSIDA). All 
individuals gave informed consent at enrolment into the EuroSIDA study. 
Inclusion and exclusion criteria 
Individuals who started or switched to an ARV regimen consisting of two drugs, one of 
which was darunavir (DRV), lopinavir (LPV), raltegravir (RAL), dolutegravir (DTG), 
rilpivirine (RPV) or etravirine (ETR), were included during prospective follow-up between 
1st July 2010 (the date when use of 2DR became increasingly common) and 31st December 
2016, with the date of starting the regimen of interest defined as baseline. Individuals were 
only included for their first eligible 2DR, or for those who were never on a 2DR during 
follow-up, for their first eligible 3DR. To ensure comparability, the 3DR group consisted of 
individuals treated with two NRTIs together with DRV, LPV, RAL, DTG, RPV or ETR as 
the third ARV during the same study period. If ritonavir or cobicistat were used as boosting 
agents, they were not considered as one of the ARV drugs in the 2DR or 3DR. Individuals 
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were aged ≥16 years at baseline and had a viral load (VL) and CD4 count measured in the 12 
months prior to baseline (see Supplementary Fig. 1). 
Definition of co-morbidities and clinical events:  
Cardiovascular disease (CVD) and D:A:D 5-year CVD risk were defined and calculated as in 
Friis-Moller et al.[24] Hypertension and dyslipidaemia followed standard definitions; systolic 
blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg and/or on 
antihypertensive drugs, and total cholesterol ≥6.2 mmol/l, high density lipoprotein cholesterol 
≤0.9 mmol/l or triglycerides >2.3 mmol/l respectively. For diabetes we followed a clinical 
definition of diabetes and/or use of antidiabetic drugs.  We calculated estimated glomerular 
filtration rates (eGFR) with the CKD-EPI creatinine equation, while chronic kidney disease 
(CKD) and D:A:D 5-year CKD risk were defined and calculated as in Mocroft et al.[25] End-
stage renal disease (ESRD) was defined as a clinical diagnosis of ESRD, or confirmed eGFR 
≤15 mL/min. (≥3 months apart).  Liver-related events (LRE) included a composite diagnosis 
of ascites, hepatic encephalopathy grade 3 or 4, hepatorenal syndrome, oesophageal variceal 
bleeding, end-stage liver disease without specifications and hepatocellular carcinoma.   
New clinical events, calculated as incidence per 1000 person years of follow up (PYFU), 
were assessed for all persons. Events included death, any new AIDS defining event 
(malignant or non-malignant), non-AIDS defining malignancy, CVD (myocardial infarction, 
stroke or invasive cardiovascular procedure), CKD or liver-related events. 
Statistical analysis: 
All analyses were performed using SAS (Statistical Analysis Software, Cary, NC, US) 
version 9.4. P-values of <0.05 were considered statistically significant and we used 95% 
confidence intervals (CIs). 
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Descriptive statistics were summarized as frequencies and proportions with χ2 P-values for 
categorical variables. For continuous variables, data were presented as medians and 
interquartile ranges (IQR), with P-values from the Wilcoxon-Mann-Whitney non-parametric 
test.  
Outcomes were assessed using logistic regression. Factors considered for univariate analyses 
were age, gender, ethnic group, region of Europe, mode of infection, time since HIV 
diagnosis, prior AIDS defining disease, baseline CD4 count, nadir CD4 count, VL, prior 
ARV exposure, number of ARVs previously exposed to, time on ARVs, prior exposure to 
NRTIs, NNRTIs, boosted PIs, INSTIs, or other ARVs, co-morbidities and risk score.  All 
multivariable logistic regression modelling shown used forward selection in order to find 
variables which contribute significantly to the model (p <0.1), with additional key variables 
forced in.   
Immunologic and virologic outcomes were assessed at 6- or 12-months after baseline, among 
all persons with the potential for 6- or 12-months follow-up. The VL and CD4 count 
immediately before the 6- or 12-months point was used for analysis or, where this was not 
available, the first count after, using at most a 16-week period either side of 6- or 12-months.  
Virologic control was defined as a VL of <400 HIV RNA copies(cp)/mL. A modified 
composite FDA snapshot endpoint (mFDA) was used to determine virologic responses at 6- 
or 12-months ± 16 weeks.  Individuals with <400 HIV RNA cp/mL in this time window were 
classed as mFDA success, while individuals with at least one of: VL ≥400 cp/mL, unknown 
VL in the time window of interest, regimen changes (switched or stopped any of the drugs in 
the regimen before the end of the period), a new AIDS-defining event or death were 
considered mFDA failures. Immunologic outcomes were evaluated as the proportion of 
individuals with a 100 cells/µL or a 25% increase in CD4 count from baseline.  
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In on-treatment analyses we estimated the proportion of individuals on a 2DR or 3DR who 
achieved a VL < 400 cp/mL at 6- or 12-months ± 16 weeks, among individuals with a known 
VL and no regimen changes. 
In order to cover VL assays used in the time period and throughout the region a cut-off <400 
cp/mL has been applied for the main analysis, while also performing sensitivity analyses 
defining mFDA and on-treatment success as <50 cp/mL at 6- or 12- months ± 16 weeks.  
Outcomes were determined for the study participants overall or stratified into three pre-
specified groups, treatment-naïve individuals, treatment-experienced individuals with 
virologic failure (≥400 cp/mL) on the previous regimen, and treatment-experienced 
individuals with virologic control (<400 cp/mL) at baseline.  
Results:  
Baseline demographic and clinical characteristics  
Of the 23071 individuals included in the EuroSIDA study, 4770 (20.7%) were eligible for 
inclusion into the analysis (Supplementary Fig. 1a), of whom 423 (8.9%) were treated with a 
2DR and 4347 (91.1%) with a 3DR.  
Two-hundred-and-eighty (66.2%) of the 2DR included a boosted PI and 334 (79.0%) an 
INSTI (note 191 (45.2%) individuals were on a PI+INSTI 2DR). The four most common 
2DR were DRV + RAL (n=153, 36.2%), DRV/r + 3TC (n=77, 18.2%), RAL + ETR (n=66, 
15.6%) and DTG + 3TC (n=39, 9.2%; see supplementary Fig. 1b). The most common third 
ARV drugs in the 3DR group were DRV/r (n=1117, 25.7%) followed by LPV/r (n=887, 
20.4%), and DTG (n=774, 17.8% (Supplementary Fig. 1c). Among the 3DR group the most 
common NRTI backbone used was tenofovir disoproxil fumarate + emtricitabine (n=2284, 
52.5%) followed by abacavir + 3TC (n=1395, 32.1%).  Baseline was significantly later for 
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those treated with a 2DR (median 31/07/14 (IQR 26/10/12 - 26/10/15)) compared to a 3DR 
(median 01/10/13 (IQR 22/03/12 - 30/03/15); p <0.0001). 
Table 1 shows the baseline demographic and clinical characteristics of persons included. 
Individuals receiving a 2DR were older than those starting 3DR (median age 52.1 years (IQR 
46.2 - 57.6) versus 46.4 years, (IQR 37.8 - 53.1). The majority in both groups were males, 
with men who have sex with men being the most common route of HIV transmission.  A 
higher proportion of those receiving a 2DR had a CD4 count >500 cells/µL and VL <400 
cp/mL compared to those receiving a 3DR. Individuals in the 2DR group were more 
extensively pre-treated prior to baseline. Apart from current smoking status (39% vs. 46%), 
persons in the 2DR group had a higher prevalence of risk factors and comorbidities including 
diabetes, CVD, LRE and CKD.   
Factors associated with treatment with a 2DR versus 3DR  
Table 2 shows the univariate and multivariable odds ratios for starting or switching to 
treatment with a 2DR versus 3DR. After adjustment, individuals from Southern Europe were 
more likely to receive a 2DR than those from Northern or Eastern Europe. Persons on a 2DR 
were more likely to have previously been treated with a boosted PI or INSTI. A high or very 
high D:A:D 5-year CVD risk score and ESRD were also associated with higher adjusted odds 
of receiving a 2DR. After adjustment for the other factors, prior exposure to NRTIs or 
NNRTIs was not significantly associated with treatment with a 2DR.  
Virologic and immunologic outcomes of 2DR versus 3DR 
VL at follow-up was available for 85.5% and 85.4% of the participants at 6 months, and for 
79.9% and 80.7% at 12 months for individuals in the 2DR and 3DR group, respectively. The 
crude proportion of individuals with controlled viral load in the on-treatment analysis was 
marginally greater for the 2DR group versus the 3DR group at 6 months; 98.3% (95%: 96.1-
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99.5) vs. 94.4% (93.5-95.2), but similar at 12 months; 98.2% (95.4-99.5) vs. 95.6% (94.5-
94.9) (Fig. 1) and consistent in a sensitivity analysis with on-treatment success defined as 
<50 cp/mL (data not shown). 
The overall proportion of mFDA success (2DR and 3DR groups combined), was 3204/4581 
(69.9%) and 2521/4230 (59.6%) at 6- and 12-months, respectively. Of the 423 individuals 
who initiated a 2DR, 398 and 344 had follow-up data available at 6- and 12-months 
respectively. Of these 289 (72.6%) had mFDA success at 6-months and 217 (63.1%) at 12 
months. Among the 4347 persons on 3DR, 4183 and 3386 had follow-up data available at 6- 
and 12-months respectively, with similar proportions of mFDA success at 6- (69.7%) and 12-
months (59.3%, p=0.2; Fig. 1).  
In the univariate analyses, there were no significant differences in the odds of mFDA success 
at either 6- or 12-months with similar results in multivariable analysis at both time points 
(Fig. 2). Baseline VL ≥400 cp/mL, HIV infection through intravenous drug use, Eastern 
European region, and lower CD4 count (≤200 cell/µL) were all associated with lower odds of 
success (data not shown). In a sensitivity analysis when applying a cut-off for mFDA success 
of <50 cp/mL, we found a small significant difference favouring 2DR in the univariate 
analysis at 6 months, but not at 12 months. The multivariable analysis was consistent with the 
main analysis at both time points (Fig. 2). 
 Regarding immunologic outcomes, there were no significant differences between 2DR and 
3DR in the proportion of individuals with a CD4 increase ≥100 cells/µL or a 25% increase in 
baseline CD4 count at either 6- or 12-months (figure 1).  In univariate analyses, there were no 
differences in the odds ratio of a CD4 increase ≥100 cells/µL at 6- or 12-months comparing 
the 2DR and 3DR, whereas in the multivariable analysis there was a small, but statistically 
significant higher likelihood of a CD4 increase ≥100 cells/µL at 6 months, but not at 12 
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months, for the 2DR group. Individuals in the two groups were equally likely to have a 25% 
increase in baseline CD4 count at both time points (Fig 2).  
Virologic and immunologic outcomes of 2DR versus 3DR stratified by treatment status at 
baseline 
Table 3 shows outcomes at 6- and 12-months, stratified by treatment status at baseline, as 
well as the numbers of those failing according to the different components of the mFDA. 
Only a small proportion of persons in the 2DR or 3DR groups were ARV-naïve when starting 
their ARV regimen, while most individuals received the 2DR or 3DR with virological control 
at baseline. In all strata, individuals in the 2DR group had a similar proportion of mFDA 
success compared to the 3DR group at both time points, regardless of prior treatment status. 
The main reasons for mFDA failure were unknown VL or regimen changes in all strata. For 
those in the 2DR group, five individuals had virological failure at 6 months and five at 12 
months (two individuals had virological failure at both time points, i.e. 8 virological failures 
in all). All except one of these virological failures occurred in individuals starting the 2DR 
after failing the previous treatment regimen. Similarly, we found a higher proportion of 
virological failures occurred in individuals treated with 3DR after a previous treatment 
failure. Among persons with virological failure at baseline, there was a higher percentage 
with mFDA success in the 2DR at 6 months, compared to 3DR (68.1%, 52.9-80.9 vs. 47.1%, 
43.1-51.2), but there was no significant difference at 12 months (52.3%, 36.7-67.5 vs. 40.3%, 
36.3-44.4). 
Incidence of clinical events 
We observed a similar incidence of clinical events during follow-up after starting a 2DR (934 
PYFU; median FU 1.7 years, IQR 0.8-3.5 years) or 3DR (11583 PYFU; median FU 2.5 
years, IQR: 1.1-4.0 years). In the 2DR group there were 40 clinical events (three AIDS-
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
defining events, 14 NADM, six CVD, five LRE and 12 CKD), giving an incidence rate (IR) 
of 42.8 events/1000 PYFU (CI 31.4-58.4). Individuals on 3DR had 356 events (69 AIDS-
defining events, 83 NADM, 48 CVD, 38 LRE and 118 CKD, IR 30.7/1000 PYFU, CI 27.7-
34.1). There were 11 deaths during FU in the 2DR group (IR 11.8/1000 PYFU, CI 95% 5.9-
21.1) and 127 deaths (IR 11.8/1000 PYFU, CI 95% 9.2-13.1) in the 3DR group.   Although 
the IRs were somewhat higher in the 2DR group, the individuals had more comorbidities at 
baseline, while the analysis was not powered to perform formal adjusted comparisons for 
these. 
Discussion:  
We here present data from the large, multicentre observational EuroSIDA cohort, examined 
uptake of and factors associated with starting or switching to a 2DR and assessed virologic 
and immunologic outcomes for individuals on 2DRs compared to 3DRs. Most of the 2DRs 
included DRV, RAL or DTG, were largely used by older individuals who were virologically 
suppressed and immunologically stable with high cumulative ARV experience, and many had 
either existing or were at high risk of developing comorbidities. Treatment with 2DRs yielded 
similar virological and immunological outcomes compared to 3DR at both 6- and 12-months.  
Individuals in the 2DR group were more likely to be from Southern Europe and less likely to 
be from Eastern or Northern Europe when compared to Western Europe. Though different 
socioeconomic, logistic and infrastructural circumstances across Eastern Europe are a 
reasonable explanation,[26] in Northern Europe it might imply a more conservative approach 
to the use of 2DR. This would be consistent with the first recommendations of 2DR treatment 
found in clinical guideline from 2014.[27] In Southern Europe, 2DR may be more commonly 
used due to lower cost and/or clinicians being more experienced with 2DRs, as many 
preliminary studies on this treatment strategy come from this region. After adjustment, 
comorbidities such as ESRD and CVD were associated with starting or switching to a 2DR, 
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although age was not, suggesting that 2DR were selected based on underlying comorbidities 
in virologic and immunologic stable persons independent of their age. 
We found no evidence that individuals treated with 2DRs had inferior virologic outcomes at 
6-or 12-months compared to 3DRs. There were no statistically significant differences in the 
overall proportion of individuals with mFDA success, across a range of sensitivity analyses, 
including pre-planned sub-group analyses according to treatment status at baseline. There 
was some evidence of a better mFDA success at 6 months in those starting a 2DR after 
previous virologic failure. These results should, however, be interpreted with caution as the 
difference was small and based on comparatively modest numbers, and we were not able to 
perform a multivariable analysis. We did not find the same association at 12 months, though 
this may reflect clinical intervention to ineffective treatment at 6 months, or the relatively 
small number of individuals in this stratum. These findings are in line with results from 
RCTs. LPV/r  or  DRV/r in combination with 3TC[7, 19] or RAL[28, 29] have been shown to be 
non-inferior compared 3DRs. For INSTI + NNRTI combinations, there is some evidence that 
RAL+ETR is a promising strategy,[18] while other trials have shown DTG + RPV to be an 
effective combination for maintaining viral suppression[13]. Likewise, positive results with 
DTG + 3TC were reported in a recent study from France,[30] and will be investigated further 
in a planned trial (ClinicalTrials.gov Identifier: NCT03446573). DTG + 3TC could also be a 
viable treatment option for ARV-naïve individuals based on reports from recent trials.[15] 
 
Regarding immunologic responses, many individuals switched to a 2DR with virologic 
suppression and a high CD4 count (>500 cells/µL). Therefore, the proportions of individuals 
with the specified increases in CD4 counts (>100 cells/µL or a >25% increase) were 
generally low (<30% of individuals).  As with the mFDA success, we did not observe any 
statistically significant differences in the proportion of individuals with a 100 cells/µL CD4 
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cell increase between the two groups at 12 months. There was a small but statistically 
significant higher proportion of persons with a CD4 cell increase >100 cells/µL at 6 months 
in the 2DR group, but this was not significant in the alternative analysis for a 25% increase in 
CD4 cells. The association may be due to chance. However, the small difference seen at 6 
months did not persist to 12 months, suggesting that any effect, if real, is transient and 
unlikely to translate into a clinical benefit.  
 
The large size of the EuroSIDA study and inclusion of a heterogeneous, geographically 
diverse population of PLWHIV in real-life clinical settings are major strengths of this 
analysis.  Another strength is that we included a variety of different 2DRs, reflecting the 
combinations in use in routine clinical care within the time period. 
Due to the observational nature of this study, confounding by indication can never be fully 
excluded. However, the main limitation of this study is, that even in this large cohort, 2DRs 
were rarely used in the period of the analysis, and we could therefore not perform analyses of 
specific regimens.  Another limitation of the study is that we did not have information on 
ARV-resistance.  Although only eight individuals in the 2DR group experienced virological 
failure, we were unable to clarify whether this was due to the occurrence of resistance.  
A further limitation is that we only considered the first 2DR of each individual in the time 
period from 1/7/2010 to 31/12/2016.  Consequently, if an individual switched from an older 
2DR, to another 2DR consisting of more contemporary drugs, the later regimen would not 
have been included. Also, due to low numbers and limited follow-up, we did not have enough 
power to adjust for relevant factors or do a formal adjusted analysis or comparison of the 
incidence of clinical events between the 2DR- and 3DR groups. To sufficiently evaluate and 
compare long-term clinical outcomes of using 2DR versus 3DR, studies with more extended 
follow-up is needed.   
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In conclusion, we found that the 2DRs in our analysis were largely used according to the 
current clinical guidelines.  Our results show that 2DRs in the period were mainly prescribed 
to ARV-experienced individuals who switched from their previous regimen with virologic 
suppression, high CD4 counts and pre-existing or higher risk of co-morbidities. Although we 
observed favourable outcomes for ARV-naïve individual starting a 2DR, the numbers were 
too low to allow meaningful conclusions. Overall, virologic and immunologic outcomes in 
individuals on 2DRs were similar to individuals on 3DRs in this selected population, in line 
with results from randomized clinical trials, although confounding by indication cannot be 
fully excluded. 
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Table 1: Baseline demographic and baseline clinical characteristics  
 
 
 2DR 3DR Total
n = ( n = (% n = (% P-
Age Group ≥50 yrs 252 (6 1565 (3 18 (3 <0.00
Gender Male 314 (7 3081 (7 33 (7 0.1
Ethnic Group White 368 (8 3767 (8 41 (8 0.8
Region of Europe* 
 
Southern 195 (4 1059 (2 12 (2 <0.00
01 Western/Central 131 (3 1146 (2 12 (2Northern 55 (1 776 (1 83 (1
Eastern 42 (1 1366 (3 14 (3
BMI (kg/m2) 
Underweight 30 (7 152 (4) 18 (4) <0.00
01 Overweight (25 91 (2 908 (2 99 (2Obese (≥ 30) 25 (6 247 (6) 27 (6)
unknown 59 (1 1060 (2 11 (2
Smoking status¤  Never smoked 140 (3 1314 (3 14 (3 0.003
2Current smoker 165 (3 2004 (4 21 (5)
Mode of infection 
MSM 164 (3 1590 (3 17 (3
0.6 IDU 105 (2 1159 (2 12 (2
Heterosexual 117 (2 1262 (2 13 (2
Other or 37 (9 336 (8) 37 (8)
HIV Diagnosis ≤ 2 yrs before 5 (1 267 (6) 27 (6) <0.00
01unknown 19 (5 503 (1 52 (1Baseline VL (cp/mL) < 400 370 (8 3235 (7 36 (7 <0.00
Baseline CD4 cell counts  
(Cells/µL) 
> 500 250 (6 2373 (5 26 (5
0.02 350 - 500 88 (2 835 (1 92 (1
200 - 350 46 (1 722 (1 76 (1
< 200 39 (9 417 (1 45 (1
Previous exposure to ARVs Previously 415 (9 3781 (8 41 (8 <0.00
01Naïve 8 (2 566 (1 57 (1Number of ARV drugs 
previously exposed to
1 to 4 57 (1 1179 (2 12 (2 <0.00
01≥ 5 357 (8 2595 (6 29 (6
Previous exposure to specific 
ARV 
NRTI 409 (9 3740 (8 41 (8 <0.00
NNRTI 286 (6 2389 (5 26 (5 <0.00
PI/b 339 (8 2542 (5 28 (6 <0.00
INSTI 115 (2 268 (6) 38 (8) <0.00
Hepatitis B HBsAg positive 16 (4 194 (5) 21 (4) 0.1 
Not tested / 39 (9 547 (1 58 (1
Hepatitis C virus Hepatitis C ab 161 (3 1800 (4 19 (4 0.000
6Not tested / 12 (3 299 (7) 31 (7)Hypertension yes 247 (5 2081 (4 23 (4 <0.00
01Unknown 22 (5 141 (3) 16 (3)Dyslipidaemia yes 334 (7 2594 (6 29 (6 <0.00
01unknown 4 (1 193 (4) 19 (4)Chronic Kidney Disease yes 41 (1 139 (3) 18 (4) <0.00
unknown 6 (1 195 (5) 20 (4) unkn
Family history of CVD yes 35 (8 300 (7) 33 (7) <0.00
01unknown 143 (3 1088 (2 12 (2
CVD 
yes 31  (7
) 
171  (4) 20
2  
(4) <0.00
01 
Diabetes yes 46 (1 211 (5) 25 (5) 0.000
NADM yes 28 (7 148 (3) 17 (4) 0.000
ESRD yes 6 (1 8 (0. 14 (0. <0.00
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¤ Past and unknown smoking status: 102 and 16 individuals and in the 2DR group, 798 and 
231 in the 3DR group respectively. 
*Region of Europe includes South and Argentina: Argentina, Greece, Israel, Italy, Portugal, 
Spain; West central: Austria, Belgium, France, Germany, Luxembourg, Switzerland; North: 
Denmark, Finland, Iceland, Ireland, Netherlands, Norway, Sweden, United Kingdom; East: 
Belarus, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Georgia, Hungary, 
Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovenia and Ukraine. 
Abbreviations; MSM: Men-sex-with-men, IDU: Injecting drug use, (N)NRTIs: 
(non)Nucleot(s)ide reverse transcriptase inhibitor, PI/b: Boosted protease inhibitor, INSTI: 
Integrase inhibitor, ARV: Antiretroviral drugs, CVD: Cardiovascular disease, HBsAg: 
Hepatitis B surface antigen, NADM: non-AIDS defining malignancy, ESRD: end-stage renal 
disease 
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Table 2: Univariate and multivariable analysis of factors associated with starting or 
switching to a 2DR. 
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*Percentage of total in specific treatment strata 
# Proportion of individuals with known viral load and without regimen change whom 
achieved virologic success (VL <400 cp/mL) at 6- or 12-months follow-up 
¤ mFDA failure: ≥1 of VL > 400 cp/mL, unknown viral load in the timeframe, regimen 
change, AIDS event or death during follow-up 
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Figure 1: Proportions of virologic success, mFDA success and immunologic responses 6- 
or 12-months ± 16 weeks after starting or switching to a 2DR or 3DR. 
 
Bars show 95% confidence intervals (CI) of proportions. 
*VL are shown for individuals who had a measurement available at 6-or 12-months ±16 
weeks and who did not change regimen at 6- or 12-months follow-up. This included 294 
individuals in the 2DR group and 3096 individuals on 3DR at 6 months (10-42 weeks) and 
221 and 2421 individual, respectively, at 12 months (36-68 weeks). 
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Figure 2: Forest plots of the OR and aOR for obtaining a virologic success < 400- or < 
50 cp/mL by mFDA and a CD4 increase >100 cells /µL or a 25% increase in CD4 count 
from baseline, at 6- or 12-months ± 16 weeks respectively.  
 
A: Odds ratio and adjusted odds ratio of mFDA success at 6-and 12-months ± 16 weeks 
depending on being on a 2DR or 3DR. Top half shows mFDA defined as < 400 cp/mL. 
Bottom half shows the sensitivity analysis defining mFDA as < 50 cp/mL. 
B:  Odds ratio adjusted odds ratios of immunologic response defined as either CD4 increase 
of > 100 cells/µL or a CD4 increase of > 25 % from baseline. Top half shows reconstitution 
at 6 months. Bottom half reconstitution at 12 months.  
The models have been adjusted for age group (<50 or ≥50 years), gender, race, region of 
Europe, mode of transmission, recent HIV diagnosis, baseline CD4 cell counts, baseline viral 
load, prior ART, liver-related events and chronic kidney disease. 
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